Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug.